Cyclic YAP‐like peptides, IAG933, palmitoylation inhibitors, and other allosteric inhibitors also disrupt the YAP–TEAD interaction,29 however, no clinical data are yet available regarding their potential efficacy in cancer treatment. This evidence concerns the gene YAP1 and cancer.